Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through innovative solutions. The company's flagship products include the Aquadex SmartFlow System and the RenalSense Clarity RMS. The Aquadex SmartFlow System is designed for patients who have not responded to diuretics, offering a clinically proven method to remove excess fluid safely. The RenalSense Clarity RMS is a continuous kidney monitoring system that provides real-time data to medical staff, enhancing patient care.
Recently, Nuwellis announced promising results from new clinical data analyses from the AVOID-HF trial. These studies highlight the effectiveness of the Aquadex System in reducing heart failure readmissions within 30 days, presenting a potential superior therapy compared to traditional diuretics. The re-analysis of the AVOID-HF data demonstrates significant benefits in managing heart failure events and hospitalizations.
Nuwellis is also advancing in pediatric care with a new, fully integrated pediatric continuous renal replacement therapy (CRRT) device. This initiative is partly funded by a $1.7 million grant from the National Institutes of Health (NIH), indicating the company's commitment to addressing the needs of young patients with limited kidney function.
The company has a robust intellectual property portfolio, including a recent patent that allows for seamless transitions between stationary and mobile operation modes, enhancing patient flexibility and care. This technology, along with ongoing clinical trials and collaborations, positions Nuwellis as a leader in fluid management and ultrafiltration therapy.
Nuwellis is headquartered in Minneapolis, with a subsidiary in Ireland, and continues to push the boundaries of medical technology to improve patient outcomes worldwide. For more information, visit www.nuwellis.com.
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, is set to release its Q1 2023 financial results on May 9, 2023. The company will hold a conference call and webcast at 9:00 AM ET to discuss the financial results and provide a general business overview. Investors can access the live webcast on Nuwellis' Investors page or by calling the designated numbers provided for U.S. and international participants.
Nuwellis specializes in treating fluid overload issues with its Aquadex SmartFlow® system, aimed at transforming the lives of affected patients. This system is designed for use in both outpatient and inpatient settings under physician supervision.
Nuwellis, Inc. (Nasdaq: NUWE) recently announced a peer-reviewed publication supporting ultrafiltration as a viable treatment for acute decompensated heart failure (ADHF), particularly for patients unresponsive to diuretics. The publication, featured in Cardiorenal Medicine Journal, reviewed data from seven trials involving 771 patients, highlighting ultrafiltration's advantages in efficient fluid removal without harming renal function. This method could reduce hospital readmissions and alleviate healthcare costs associated with ADHF. Nuwellis aims to establish ultrafiltration as the standard of care through increased awareness and clinical evidence.
Nuwellis, Inc. (Nasdaq: NUWE) announced that the Company’s independent directors approved equity awards on February 23, 2023, under the 2021 Inducement Plan. These awards were granted as material inducements for six new hires. The equity awards consist of options to purchase a total of 2,514 shares at an exercise price of $8.27 per share, equal to the closing stock price on the grant date. The options have a ten-year term and vest over four years, with 25% vesting after one year and the remainder vesting monthly, contingent on ongoing employment.
Nuwellis focuses on the Aquadex SmartFlow system for treating fluid overload in patients.
Nuwellis, Inc. (NASDAQ: NUWE) reported a 42% increase in Q4 revenue, reaching $2.3 million, while full-year revenue grew by 8% to $8.5 million for 2022. The company achieved a gross margin of 56.9% in Q4, up 250 basis points year-over-year. Key segments included Pediatrics (92% growth), Heart Failure (47% growth), and Critical Care (24% growth). Nuwellis entered an exclusive licensing agreement for the Selective Cytopheretic Device to treat pediatric Acute Kidney Injury. Peer-reviewed data demonstrated significant improvements in hospitalizations related to heart failure and kidney replacement therapy survival rates. The company ended 2022 with $18.3 million in cash.
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology firm, announced its participation in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023. Nestor Jaramillo, President and CEO, and Lynn Blake, CFO, will present at 9:20 AM ET and hold investor 1x1 meetings. The presentation will be available via a webcast on the company's website, where it will also be archived for later access. Nuwellis focuses on transforming patient care for those with fluid overload through its Aquadex SmartFlow® system, aimed at providing effective ultrafiltration therapy.
Nuwellis, Inc. (Nasdaq: NUWE) emphasizes the significance of maintaining intravascular volume during cardiac procedures in response to a recent editorial in The Annals of Thoracic Surgery. The editorial highlights ultrafiltration's role in preventing cardiac surgery-associated acute kidney injury (CSA-AKI), noting that up to 80% of patients may experience stage 1 or greater CSA-AKI. The authors challenge the reliance on diuretics, advocating for ultrafiltration as a viable alternative, particularly for patients resistant to diuretics. Dr. John Jefferies from Nuwellis expresses optimism regarding the validation of their Aquadex® technology, supported by data showing a 100% survival rate in a study involving high-risk CABG patients.
FAQ
What is the current stock price of Nuwellis (NUWE)?
What is the market cap of Nuwellis (NUWE)?
What does Nuwellis, Inc. specialize in?
What is the Aquadex SmartFlow System?
What recent clinical trials have Nuwellis conducted?
What is the RenalSense Clarity RMS?
What innovations has Nuwellis introduced for pediatric patients?
Where is Nuwellis headquartered?
How does the Aquadex SmartFlow System benefit patients?
Does Nuwellis have any recent patents?
What partnerships does Nuwellis have?
What is the focus of Nuwellis' business strategy?
